News

The FDA recently proposed a new rule requiring standardized asbestos testing in talc-containing cosmetics to protect consumers from potential harm.

In case you missed it, this week we had news about a significant dual treatment approach for AD, organic filter-based sunscreens for sensitive skin, what we’re most looking forward to in 2025, and more.

Explore the top headlines of the week including 2025 PDUFA dates, 2024 interview insights, and awareness dates to add to your calendar.

After 8 weeks of use, the product showed improvements in skin sensitivity, transepidermal water loss, and skin corneum hydration.

We're welcoming 2025 with dermatology innovations, expert insights on chronic hand eczema, and new leadership at Dermatology Times.

Real-world data from TARGET-DERM AD revealed that those with both reduced itch and clearer skin had the lowest levels of disease burden.

Unlike bakuchiol, which exhibited toxicity at higher concentrations, SME demonstrated no cytotoxic effects in vitro.

The dermatology market remains an exciting space with strong demand for its valuable services, bolstered by positive US economic trends and robust consumer spending.

Researchers found significant clinical benefits and tolerability with dual therapy for patients unresponsive to dupilumab alone.

Dermatology Times has compiled a list of dermatological meetings taking place during the month of January.

Dermatology Times asked our readers to share what conferences they are looking forward to in 2025.

Click here to view Dermatology Times' comprehensive list of health awareness days, months, weeks, and initiatives for 2025.

Experts in the field shared insights with Dermatology Times on what they're looking forward to most in the new year.

Dermatology Times is reviewing some of the most anticipated PDUFA dates of the upcoming year.

Explore the standout moments and expert insights from Dermatology Times' Cutaneous Connection podcast episodes in 2024.

Discover the most impactful insights and expert advice from Dermatology Times' 2024 Interview Intersection column.

As 2024 comes to a close, Dermatology Times is taking a look back at the unique insights and updates shared by nurse practitioners and physician assistants.

As 2024 comes to a close, Dermatology Times is taking a look back at the studies and clinical research from the year.

As 2024 comes to a close, Dermatology Times is taking a look back at the studies, therapies, and advances in skin cancer this year.

As 2024 comes to a close, Dermatology Times is taking a look back at the studies, therapies, and advances in acne this year.

Find out what the top 10 most popular articles of 2024 were from Dermatology Times.

Catch up on Dermatology Times conference coverage from July through December of this year.

As 2024 comes to a close, Dermatology Times is taking a look back at the studies, therapies, and advances in hidradenitis suppurativa this year.

Catch up on coverage of FDA-approved drugs in the second half of 2024.

Explore the top dermatology news of 2024, highlighting breakthroughs, innovations, and key clinical insights shaping the future of skin care and treatment.

Catch up on Dermatology Times conference coverage from January through June of this year.

As 2024 comes to a close, Dermatology Times is taking a look back at the studies, therapies, and advances in atopic dermatitis this year.

Catch up on coverage of FDA-approved drugs in the first half of 2024.

As 2024 comes to a close, Dermatology Times is taking a look back at the studies, therapies, and advances in aesthetic/cosmetic dermatology this year.

As 2023 comes to a close, Dermatology Times is taking a look back at the studies, therapies, and advances in psoriasis this year.